Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | AKT1 | P31749 | 4/20 | 0.71 |
| ▸ | PKM | P14618 | 3/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178178 | 0.87 | PKM (0.74) | ALDH1A1AKT1PKMCA1CA2 | |
| SCHEMBL2196247 | 0.87 | AKT1 (0.64) | ALDH1A1AKT1PKMCA1CA2 | |
| SCHEMBL11893077 | 0.86 | AKT1 (0.76) | ALDH1A1AKT1PKMCA1CA2 | |
| SCHEMBL328514 | 0.84 | ALDH1A1 (0.68) | ALDH1A1AKT1PKMCA1CA2 | |
| SCHEMBL5391648 | 0.84 | SMN1; SMN2 (0.64) | ALDH1A1AKT1PKMMEN1KMT2A | |
| SCHEMBL5394726 | 0.83 | ALDH1A1 (0.67) | ALDH1A1AKT1PKMCA1CA2 | |
| SCHEMBL282565 | 0.83 | CA1 (1.00) | ALDH1A1AKT1PKMCA1CA2 | |
| SCHEMBL287025 | 0.83 | AKT1 (1.00) | ALDH1A1AKT1PKMMEN1KMT2A | |
| SCHEMBL328518 | 0.83 | ALDH1A1 (0.69) | ALDH1A1AKT1PKMCA1CA2 | |
| SCHEMBL286763 | 0.83 | ALDH1A1 (1.00) | ALDH1A1AKT1PKMCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | claimed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | claimed |
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | disclosed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-2428504-B1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | UNIV TEXAS (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2428504-B1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | UNIV TEXAS (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2428504-A1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | The Board of Regents of the University of Texas System (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2428504-A1 | Small molecule inhibitors of the pleckstrin homology domain and method for using same | The Board of Regents of the University of Texas System (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011082400-A2 | MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082400-A2 | MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2011032169-A2 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PHUSIS THERAPEUTICS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2009129267-A2 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144066-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | ALDH1A1 4424/4885AKT1 92/4885PKM 2714/4885 |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | ALDH1A1 4424/4885AKT1 92/4885PKM 2714/4885 |
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | AKT3, AKT1, AKT2 | ALDH1A1 4551/4885AKT1 2/4885PKM 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.